STRATEC SE

Earnings Release • Mar 9, 2006

News Details

Ad-hoc | 9 March 2006 15:16

STRATEC reports high-margin growth for 2005 financial year

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC reports high-margin growth for 2005 financial year – Annual net income increases by 58.3% to EUR 4.397 million – Sales rise by 17.0% to EUR 47.297 million – At 14.6%, EBT margin is considerably above budget Birkenfeld, March 9, 2006 The Board of Management of STRATEC Biomedical Systems AG, which is listed in the German Prime Standard and Gate-M segments, hereby announces the preliminary unaudited results of the STRATEC Group for the 2005 financial year pursuant to IFRS (International Financial Reporting Standards) and in line with Section 15 of the German Securities Trading Act (WpHG). Key Figures (EUR 000s) 2005 2004 Change Sales 47,297 40,442 + 17.0% Overall Performance 48,415 39,207 + 23.5% EBITDA 8,281 5,711 + 45.0% EBIT 7,248 4,707 + 54.0% EBT 6,904 4,464 + 54.7% Annual net income 4,397 2,778 + 58.3% Earnings per share (EUR) 1.29 0.84 + 53.6% The STRATEC Group has 191 employees (previous year: 168). ————————————————————————— Informationen und Erläuterungen des Emittenten zu dieser Ad-Hoc-Mitteilung: The wholly-owned subsidiary Robion AG was included in the consolidated financial statements for the first time as of December 31, 2005. In view of its comparatively minor material significance, the wholly-owned subsidiary STRATEC NewGen GmbH continues not to be consolidated. The results of STRATEC NewGen GmbH are reported in their entirety as other operating expenses and as other provisions at STRATEC Biomedical Systems AG. The preliminary unaudited earnings figures of the STRATEC Group for the 2005 financial year are in excess of all analysts’ forecasts available to the company. The calculation of the key earnings per share figure has already taken prorated account of the increased number of shares resulting from the 10% capital increase undertaken on September 27, 2005. Excluding the effects of this capital increase, the earnings per share figure calculated on the basis of the preliminary unaudited figures for the 2005 financial year would amount to Euro 1.33. The definitive figures for the 2005 financial year will be presented and commented on in the Annual Press Conference Call to be held on April 27, 2006. Press representatives, investors and analysts wishing to take part in this telephone conference are kindly requested to register with our Investor Relations team (Tel: +49 (0)7082 7916-190). The 2005 Annual Report will be available for downloading from our website with effect from April 27, 2006. The Board of Management and Supervisory Board will discuss the dividend to be distributed, among other matters, at the meeting of the Supervisory Board held to adopt the financial statements, which is expected to take place on April 6, 2006. Our Annual General Meeting for the 2005 financial year will be held in Pforzheim on June 23, 2006. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical Systems AG’, as well as the wholly-owned subsidiaries ‘STRATEC NewGen GmbH’ and ‘Robion AG”. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 (0)7082 7916 190 Fax: +49 (0)7082 7916 999 E-Mail: ir@stratec-biomedical.de (c)DGAP 09.03.2006 ————————————————————————— language: English emitter: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland phone: +49 (0)7082 7916 0 fax: +49 (0)7082 7916 999 email: info@stratec-biomedical.de WWW: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 indexes: stockmarkets: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf, München End of News DGAP News-Service ————————————————————————-